Skip to main content
Genomictree Inc. logo

Genomictree Inc. — Investor Relations & Filings

Ticker · 228760 ISIN · KR7228760005 KO Professional, scientific and technical activities
Open in API
Filings indexed 237 across all filing types
Latest filing 2024-07-05 Director's Dealing
Country KR South Korea
Listing KO 228760

About Genomictree Inc.

https://genomictree.com/eng/

Genomictree Inc. is a molecular diagnostics company that develops and commercializes products for the early detection and diagnosis of cancer. The company specializes in epigenomics, utilizing its proprietary genomic-scale discovery tools to identify DNA methylation biomarkers. Its flagship product line, EarlyTect®, offers non-invasive tests for the early screening of colorectal, lung, and bladder cancers. Additionally, Genomictree provides AccuraTect™, a companion diagnostic test for cancer. The company's mission is to improve patient quality of life and reduce medical costs through accessible and accurate early-stage cancer detection.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). This is a standard regulatory filing used to disclose insider transactions or changes in share ownership by company directors and executives. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS).
2024-07-05 Korean
주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from Genomictree, specifically regarding the 'Decision to Dispose of Treasury Shares' (자기주식 처분 결정). This filing details the company's plan to distribute treasury shares to employees as part of a stock-based compensation scheme (RSU). Since the document reports the company's action of disposing of its own shares, it falls under the 'Transaction in Own Shares' category.
2024-07-02 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company Genomictree (지노믹트리) covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial data, business operations, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-14 Korean
전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding the exercise of conversion rights (전환청구권행사) for convertible bonds into shares. This involves a change in the company's capital structure as debt is converted into equity. According to the filing definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2024-04-23 Korean
기타경영사항(자율공시) ((주)지노믹트리 제1회차 전환사채(CB) 취득 후 재매각의 건)
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) regarding the resale of convertible bonds (CB) previously acquired by the company. It details the transaction terms, purpose (securing R&D funds), and financial impact. This falls under 'Capital/Financing Update' as it relates to the company's capital structure and financing activities.
2024-04-19 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of a General Meeting of Shareholders (정기주주총회결과) for the company 'Genomictree'. It details the approval of financial statements, election of directors, and remuneration limits. This falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2024-03-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.